

Referenser: Myalgisk encefalomyelit: På väg från medicinskt oförklarat tillstånd till medicinsk sjukdomsmodifierande behandling?

White PD. What causes prolonged fatigue after infectious mononucleosis: and does it tell us anything about chronic fatigue syndrome? *J Infect Dis*. 2007 Jul 1;196(1):4-5.

ME-CFS Primer Education (2014 revision). International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. [http://iacfsme.org/ME-CFS-Primer-Education/News/News-Related-Docs/2014/ME-CFS-Primer-for-Clinical-Practitioners-\(2014-rev.aspx](http://iacfsme.org/ME-CFS-Primer-Education/News/News-Related-Docs/2014/ME-CFS-Primer-for-Clinical-Practitioners-(2014-rev.aspx) Hämtat 11.10.2015

CFS-ME. Helsedirektoratet. <https://helsedirektoratet.no/cfs-me> Hämtat 11.10.2015

ME/CFS (Kroniskt trötthetssyndrom). VISS, Stockholms läns landsting.

<http://www.viss.nu/Handlaggning/Vardprogram/Nervsystemet-och-smarta/ME-CFS/> Hämtat 11.10.2015

ME/CFS-mottagning, Stora Sköndal

<http://www.storaskondal.se/varverksamhet/neurologiskrehabilitering/mecfsmottagning.4.7094d66714c5e4e34ccebc24.html> Hämtat 11.10.2015

Gottfries Clinic <http://www.gottfriesclinic.se> Hämtat 11.10.2015

Myalgisk Encefalomyelit (ME) G93.3. Gotahälsan <http://www.gotahalsan.se/sv/myalgisk-encefalomyelit/> Hämtat 11.10.2015

ME/CFS-behandling och rehabilitering. Avtalsinformation, Vårdgivarguiden, Stockholms läns landsting <http://www.vardgivarguiden.se/avtalsinformation/avtalsinformation/varval-stockholm/mecfs/> Hämtat 11.10.2015

Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG. Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial. *Eur J Pain*. 2002;6(6):455-66.

Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. *PLoS One*. 2011 Feb 23;6(2), Elfaitouri A, Herrmann B, Bölin-Wiener A, Wang Y, Gottfries CG, Zachrisson O, Pipkorn R, Rönnblom L, Blomberg J. Epitopes of microbial and human heat shock protein 60 and their recognition in myalgic encephalomyelitis. *PLoS One*. 2013 Nov 28;8(11):

Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, Onoe K, Fukuda S, Kawabe J, Takahashi K, Kataoka Y, Shiomi S, Yamaguti K, Inaba M, Kuratsune H, Watanabe Y. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study. *J Nucl Med*. 2014 Jun;55(6):945-50.

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. *PLoS One*. 2011;6(10)

Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. *PLoS One*. 2015 Jul 1;10(7)

Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Fluge Ø, Mella O, Scheibenbogen C. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. *Brain Behav Immun*. 2015 Sep 21. pii: S0889-1591(15)30020-9. doi: 10.1016/j.bbi.2015.09.013. [Epub ahead of print] PubMed PMID: 26399744.

B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. (RituxME)

<https://clinicaltrials.gov/ct2/show/NCT02229942?term=rituximab+AND+ME&rank=1> Hämtat 11.10.2015

Cytokine Inhibition in Chronic Fatigue Syndrome Patients (CiCFS). ClinicalTrials.gov, U.S. National Institute of Health

<https://clinicaltrials.gov/ct2/show/NCT02108210?term=anakinra+AND+CFS&rank=1> Hämtat
11.10.2015